Where does histotripsy fit into hepatocellular carcinoma care?
Cancer · 01.08.2026 · 132 (15)
DOI: 10.1002/cncr.70547 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 27.07.2026. Verfasst von Kelsey S Lau-Min und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, Mass General Brigham Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, High-Intensity Focused Ultrasound Ablation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Histotripsy is a novel ultrasound‐guided ablation technique that has been approved by the US Food and Drug Administration as a medical device for the noninvasive destruction of liver tumors. The noninvasive, nonthermal, nonionizing mechanical mechanism by which it destroys tumor tissues makes it an appealing local therapy option in the treatment of patients with early‐stage hepatocellular carcinoma (HCC). In this article, the authors review the current evidence base for histotripsy in HCC and explore its potential role in routine care based on technical, safety, and clinical considerations. They then describe the evidence gaps that remain with respect to histotripsy’s treatment efficacy, comparative effectiveness, and safety relative to established local therapy options including thermal ablation, transarterial chemoembolization and radioembolization, and stereotactic body radiotherapy. Although the current body of evidence supports the technical feasibility, short‐term safety, and early local tumor control of histotripsy in the treatment of patients with HCC, standardized response assessments, rigorous prospective evaluations of durable oncologic outcomes, and direct comparisons with existing therapies in well‐defined patient populations are still needed before histotripsy can be fully integrated into standard HCC care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Medicine, Mass General Brigham Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.
- Division of Surgical Oncology, Department of Surgery, Mass General Brigham and Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Kelsey S Lau-Min, Jiping Wang
Förderung
- NCI NIH HHS
Zitieren
APA
Lau-Min, K. S., & Wang, J. (2026). Where does histotripsy fit into hepatocellular carcinoma care?. Cancer, 132(15). https://doi.org/10.1002/cncr.70547
Vancouver
Lau-Min KS, Wang J. Where does histotripsy fit into hepatocellular carcinoma care?. Cancer. 2026;132(15). doi:10.1002/cncr.70547
BibTeX
@article{LauMin2026,
author = {Lau-Min, Kelsey S and Wang, Jiping},
title = {Where does histotripsy fit into hepatocellular carcinoma care?},
journal = {Cancer},
year = {2026},
volume = {132},
number = {15},
doi = {10.1002/cncr.70547}
}
EUVIMED